Neurocritical Care Society Guidelines Update: Lessons from a Decade of GRADE Guidelines

Lori K. Madden1*, Venkatakrishna Rajajee2, Theresa Human3, Mark S. Wainwright4, Mary Guanci5, Shraddha Mainali6, Shaun Rowe7, Diane McLaughlin8, John Lunde9, Abhijit Lele10 and Herb Fried11

© 2021 The Author(s)

Keywords: Evidence-based medicine, Grading of recommendations assessment, Development and evaluation, Clinical practice guideline, Neurocritical care, Methodology, Systematic review

Introduction

The Neurocritical Care Society (NCS) launched its clinical practice guideline program in 2012 with the publication of “Guidelines for the Evaluation and Management of Status Epilepticus” [1]. Work on this guideline coincided with the development of standards for trustworthy clinical practice guidelines by the Institute of Medicine (now the National Academy of Medicine) in 2011 [2]. These standards highlighted the need for rigorous and consistent evidence-based methodology aimed at producing clear, actionable recommendations relevant to the individual patient encounter. The NCS Guideline Committee (GC) made the prescient decision to adopt and implement an emerging methodology, Grading of Recommendations Assessment, Development and Evaluation (GRADE) [3], which has since been adopted or endorsed by more than 100 organizations worldwide. Over the course of the past decade, NCS has produced a number of guidelines and related projects, the majority of which used methodology derived from GRADE publications (see Table 1). However, as our understanding of the requirements of GRADE deepened, it became clear that our application of the methodology across projects was inconsistent and generally fell short of the necessary rigor in various ways. On the basis of this growing insight, the NCS GC developed and is implementing a number of significant improvements in our guideline procedures.

The aim of this article is to introduce and explain the basis for these changes. To that end, rather than reviewing in detail individual NCS projects with widely varying formats and objectives and rotating leadership, we chose to begin by setting forth the requirements criteria in the development of these guidelines. In 2020, the US GRADE Working Group critically reviewed GRADE guidelines published in the National Guideline Clearinghouse [4]. Of the guidelines studied in this sample, which included two from NCS, nearly half did not comply with one or more of the key GRADE criteria for appropriate application of the methodology. Most commonly lacking were GRADE evidence profiles and evidence summaries, as well as explicit consideration of all four central domains required to move from evidence to recommendation. Those domains include certainty of evidence, balance of benefits to harms, patients’ values and preferences, and resource use and equity.
for consistent and trustworthy GRADE guidelines. On the basis of the lessons learned from an examination of our own published projects and those of other societies, we summarize the changes necessary to bring our guidelines up to the highest contemporary standards. Thus, between December 2019 and June 2020, the NCS GC undertook a project to review existing best practices for guideline development using a comprehensive survey. For this purpose, we selected organizations with specialty interests overlapping with the NCS and others that have adopted GRADE methodology for guideline development (see Table 2 for full list). The GC members examined published policies and procedures for each organization and, when possible, contacted a member of the organization’s guidelines committee for additional questions and clarifications (see Supplemental Content Table 1). Note that details of the identified organizations’ procedures are based on the authors’ best understanding using available information during this limited time window and may have changed since then. Through the review process, we have identified three broad themes in guideline development: (1) topic, scope, and panel; (2) systematic review; and (3) developing recommendations. Below, we discuss NCS methodology for guideline development under these three major themes.

### Table 1  
**NCS guidelines and projects to date**

| Title                                                                 | Year       | Type               | GRADE |
|----------------------------------------------------------------------|------------|--------------------|-------|
| Critical Care Management of Patients Following Aneurysmal Subarachnoid Hemorrhage | 2011       | Consensus statement | +     |
| Guidelines for the Evaluation and Management of Status Epileptics     | 2012       | Guideline          | +     |
| Consensus Summary Statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care | 2014       | Consensus statement | +     |
| Evidence-Based Guidelines for the Management of Large Hemispheric Infarction | 2015       | Guideline          | +     |
| Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage | 2015       | Guideline          | +     |
| Prophylaxis of Venous Thrombosis in Neurocritical Care Patients       | 2015       | Guideline          | +     |
| Recommendations for the Critical Care Management of Devastating Brain Injury: Prognostication, Psychosocial, and Ethical Management | 2015       | Position statement  | +     |
| The Insertion and Management of External Ventricular Drains: An Evidence-based Consensus Statement | 2016       | Consensus statement | +     |
| The Implementation of Targeted Temperature Management: An Evidence-Based Guideline from the Neurocritical Care Society | 2017       | Guideline          | +     |
| Standards for Neurologic Critical Care Units                        | 2018       | White paper        | –     |
| Clinical Performance Measures for Neurocritical Care                | 2019       | White paper        | –     |
| Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients | 2020       | Guideline          | +     |
| Neurocritical Care Resource Utilization in Pandemics                 | 2020       | Position statement  | –     |
| Critical Care Management of Patients Following Aneurysmal Subarachnoid Hemorrhage Update | Est 2021   | Guideline          | +     |
| Antiepileptic Drug Prophylaxis in Neurocritical Care                 | Est 2022   | Guideline          | +     |
| Neuropredictive in Neurocritical Care                                | Est 2022   | Guideline          | +     |
| Guidelines for the Evaluation and Management of Status Epilepticus Update | Est 2023   | Guideline          | +     |

*Est, Estimated completion date; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NCS, Neurocritical Care Society; +, GRADE methodology consulted for product development; –, No GRADE methodology utilized*

### GRADE Guideline Methodology

#### Topic, Scope, and Panel

Regardless of methodology, the success of a guideline project depends greatly on a systematic approach and planning at inception. Topic selection, determination of scope, and identification of key clinical questions are critical elements in determining the feasibility of the project. Criteria developed by the GC for topic selection and current GRADE guidance for the development of clinical questions are discussed in detail below.

The guideline co-chairs are selected from a pool of subject matter experts from multidisciplinary backgrounds who have demonstrated skill in managing complex projects and ideally have experience in the application of GRADE methodology. After identification of guideline co-chairs, selection of the writing panel is the next priority. Panel members may be selected from a pool of volunteer NCS members or may be nominated by the co-chairs with GC oversight. Although these members will also be subject matter experts, it is not required that they have experience with GRADE. The key principle is that the panel must be diverse and must attempt to represent all the stakeholders affected by the recommendations developed by the guideline. Accordingly, the NCS GC aims for a balance among physicians, nurses,
pharmacists, physician assistants, and advanced practice nurses. Type of practice setting (academic versus community) and geographic diversity are considered, along with traditional metrics of diversity among panel members. Panelists from varied related specialty areas, such as rehabilitation, neurological surgery, epileptology, or other relevant areas, may also be included on the basis of the topic. A more recent addition to this process involves engagement with health care consumers. As such, the panel will recruit patient or family representatives. Incorporation of the patient/family perspective can be invaluable in deciding on patient-centered outcomes and offering insight into the impact of recommendations.

It is often difficult for organizations to assemble and retain an internal team of methodologists with adequate expertise in GRADE and experience in performing systematic reviews. Basic criteria for this role have been suggested by the GRADE Working Group. Our survey has shown that many organizations enlist professional methodologists for this purpose (see Table 3). There are important benefits in this approach, which is discussed below.

### Systematic Review

GRADE is a comprehensive tool for rating the quality of evidence and grading the strength of recommendations for specific clinical questions (see Fig. 1 for schematic of the GRADE approach). The vehicle for this process of acquiring and assessing or adjudicating the evidence is the systematic review (SR). An SR is a highly

---

**Table 2 Organizations identified for GC survey**

| Organization                                                                 | GRADE methodology Y/N | External methodologist Y/N | Public member Y/N | Good practice statements Y/N |
|------------------------------------------------------------------------------|------------------------|-----------------------------|-------------------|-----------------------------|
| Neurocritical care society                                                   |                        |                             |                   |                             |
| Agency for Healthcare Research and Quality                                    |                        |                             |                   |                             |
| American Academy of Neurology                                                |                        |                             |                   |                             |
| American College of Chest Physicians                                          |                        |                             |                   |                             |
| American Academy of Family Physicians                                         |                        |                             |                   |                             |
| American Academy of Nurse Practitionans                                       |                        |                             |                   |                             |
| American Association of Critical Care Nurses                                 |                        |                             |                   |                             |
| American Association of Neurological Surgeons/Congress of Neurological Surgeons |                        |                             |                   |                             |
| American Association of Neuroscience Nurses                                  |                        |                             |                   |                             |
| American College of Surgeons, Trauma Quality Improvement Program              |                        |                             |                   |                             |
| American Epilepsy Society                                                    |                        |                             |                   |                             |
| American Heart Association                                                   |                        |                             |                   |                             |
| Brain Trauma Foundation                                                       |                        |                             |                   |                             |
| Centers for Disease Control and Preventionb                                  |                        |                             |                   |                             |
| Eastern Association for the Surgery of Traumaab                               |                        |                             |                   |                             |
| Endocrine Society                                                             |                        |                             |                   |                             |
| European Society of Intensive Care Medicinea                                 |                        |                             |                   |                             |
| European Stroke Organization                                                  |                        |                             |                   |                             |
| Hospital Infection Control Practices Advisory Committee                       |                        |                             |                   |                             |
| Latin American Brain Injury Consortiuma                                       |                        |                             |                   |                             |
| Society for Neuroscience in Anesthesia and Critical Carea                     |                        |                             |                   |                             |
| Society of Critical Care Medicineab                                            |                        |                             |                   |                             |
| US Preventive Services Task Forcea                                            |                        |                             |                   |                             |
| World Health Organizationb                                                    |                        |                             |                   |                             |

---

**Table 3 Organizations and selected guideline practices**

| Organization                                                                 | GRADE methodology Y/N | External methodologist Y/N | Public member Y/N | Good practice statements Y/N |
|------------------------------------------------------------------------------|------------------------|-----------------------------|-------------------|-----------------------------|
| NCS                                                                          | Y                      |                             | Y                 | Y                           |
| AACN                                                                         | N                      |                             | N                 | Y                           |
| AAN                                                                          | N                      |                             | Y                 | Y                           |
| AANN                                                                         | Y                      | N                            | Y                 | N                           |
| AANS/CNS                                                                     | Y                      | N                            | N                 | N                           |
| ACCP                                                                         | Y                      |                             | Y                 | Y                           |
| AHA                                                                          | N                      |                             | N                 | N                           |
| CDC                                                                          | Y                      | N                            | Y                 | N                           |
| EAST                                                                         | Y                      | N                            | Y                 | Y                           |
| Endocrine Society                                                            | Y                      |                             | Y                 | Y                           |
| ESICM                                                                        | Y                      | N                            | N                 | Y                           |
| SCCM                                                                         | Y                      |                             | Y                 | Y                           |
| USPSTF                                                                       | N                      | Y                            | Y                 | N                           |
| WHO                                                                          | Y                      | Y                            | Y                 | N                           |

---

AACN, American Association of Critical Care Nurses; AAN, American Academy of Neurology; AANN, American Association of Neuroscience Nurses; AANS, American Association of Neurological Surgeons; ACCP, American College of Chest Physicians; AHA, American Heart Association; CDC, Centers for Disease Control and Prevention; CNS, Congress of Neurological Surgeons; EAST, Eastern Association for the Surgery of Trauma; ESICM, European Society of Intensive Care Medicine; N, no; NC, Neurocritical Care Society; SCCM, Society of Critical Care Medicine; USPSTF, US Preventive Services Task Force; WHO, World Health Organization; Y, yes.
structured process that aims to generate reproducible findings and conclusions from a given set of data, that is, two different panels to follow this rigorous process, they should ideally arrive at the same result from a given evidence base. Consistency and transparency in methods and judgments are required to achieve this.

The first step in the SR is the careful crafting of focused clinical questions [5]. The generally accepted format is PICO: population, intervention (or diagnostic test) of interest, comparator (another treatment, gold standard diagnostic test, or usual care), and outcomes (which must include patient-important benefits as well as harms). Although timing and setting are usually considered to be features of outcome and population, respectively, they may be added (PICOTS) when the panel wishes to highlight them. Finally, in our experience from a practical standpoint, a range of six to fifteen PICO/PICOTS questions is preferred.

The PICO question unifies all the steps in the SR and recommendation process. Each PICO element must be clear and specific or the entire SR project may be compromised. For example, the population may include heterogeneous subgroups with different baseline risks for an outcome. Multiple interventions may require a more sophisticated network analysis. Lack of a clear comparator may make it difficult or impossible to generate an effect size for the intervention. If not strongly linked to patient-important outcomes, use of surrogate outcome measures (such as biomarkers) may require downgrading of the evidence quality.

Once PICO questions have been refined with up to seven patient-important outcomes that have been identified with ranking of relative importance (critical,
important, and not important), a search strategy is developed with a research librarian. Important trade-offs between global inclusiveness (e.g., whether to consider multiple language sources, unpublished or “gray” literature, etc.) and feasibility (retrieving a large number of irrelevant or unusable studies) require close collaboration between the panel and the information specialist. Search strategies that are too broad will produce an avalanche of irrelevant studies, whereas stringent strategies are likely to miss important evidence. Once a search strategy is applied, the articles are then screened for inclusion or exclusion by using SR software (e.g., DistillerSR or Covidence). The vast majority of references are removed via screening in this multilayered, labor-intensive process.

The next task, data extraction from the selected studies, introduces important innovations of the GRADE approach. First, it does not assign an evidence quality rating (high, moderate, low, or very low) to any individual study. Rather, evidence quality (certainty in the evidence) is an attribute of the entire body of evidence for a given outcome. What GRADE evaluates in each study is its risk of bias (otherwise known as study limitations). In this process, randomized controlled trials (RCTs) are initially considered to be of high quality because randomization is felt to be the only secure way to eliminate residual confounding and bias in patient selection; nonrandomized (observational) studies (NRS) begin as low quality.

In neurocritical care, there is a paucity of high-quality evidence, particularly in terms of well-designed and well-executed RCTs. Thus, there is increasing interest in the wide variety of NRS. Cochrane’s risk of bias tool uses domains familiar to many as the appropriate instrument to apply to RCTs [6]. Many tools have been proposed and used for NRS (Newcastle–Ottawa Scale, for example) [7]. However, a new and more detailed tool, the Risk of Bias In Nonrandomized Studies of Interventions (ROBINS-I) has been introduced in GRADE to evaluate NRS [8, 9], and other tools are available for diagnostic tests (QUality Assessment of Diagnostic Accuracy Studies-2) or for prognostic studies (Prediction model of Risk Of Bias ASeessment Tool and QUality In Prognostic Studies, for example) [10, 11].

The second important innovation of GRADE is that evidence is aggregated, and quality of evidence is assessed, according to the critical and important outcomes prespecified in the PICO question [12]. That is, GRADE is “outcome centric” and recognizes that the quality of evidence available for each outcome may often be different.

Risk of bias is only the first of the domains GRADE uses for assessing the quality of a body of evidence (see Fig. 2). Four other domains may result in downgrading a body of evidence for an outcome: inconsistency between studies, indirectness, imprecision, and other considerations, including publication bias. GRADE considers three domains that might result in rating up: magnitude of effect, dose–response gradient, or plausible unmeasured confounders, which might increase or decrease the effect, if present. The writing panel then makes judgments about whether limitations in each domain are serious or very serious. The quality of evidence for each outcome is then globally adjudicated by the panel. Guideline developers (but not systematic reviewers) then review all the information to make a final decision about which outcomes are critical and which are important. This concludes with a final decision regarding the rating of overall quality of evidence across critical outcomes for the clinical question.

An existing high-quality published SR could be adapted or adopted for use in a new guideline, but more commonly, a new SR is performed by the writing group itself. This has been the practice for NCS guidelines. Our experience over a decade of work has highlighted two interrelated problems with this approach. The first problem is that to apply GRADE methodology properly, dedicated study, training, and experience are required. This is difficult to achieve in a volunteer organization, such as NCS, in which there is little carryover in writing group personnel from one project to another, resulting in a lack of consistency and institutional memory.

A second problem, which contributes to the first, is the heavy workload encountered by the panel of volunteer subject matter experts in screening and extracting data from hundreds or thousands of studies. Knowledge and experience gained in each project do not carry forward seamlessly to the next. Experienced panelists find it difficult to commit to another project, realizing the labor required to complete a guideline. Moreover, in recent years there have been many important advances and refinements in GRADE methodology and in clinical epidemiology; the earliest GRADE publications lacked necessary specific and detailed guidance. Thus, a guideline methodologist faces the additional challenge of providing expertise in a field undergoing rapid evolution.

With the widespread adoption or endorsement of GRADE by medical societies and health care organizations worldwide, the need for appropriately trained methodologists to assist in creation of high-quality GRADE guidelines has become paramount. Inappropriate use of GRADE methodology has been described by senior GRADE authors [4]. The GRADE Working Group has suggested a set of fundamental proficiencies and experiences that would be desirable in a methodologist, which include (1) basic knowledge of statistics, study design, and epidemiology; (2) GRADE-specific training through workshops, webinars, familiarity with all articles in the
Developing Recommendations

A defining feature of GRADE is the structured manner in which it moves from evidence to recommendation. An SR produces an evidence summary and judgment of certainty in the evidence that is relevant for the specified population. What is lacking in an SR, and what is required in a guideline, is a framework for describing the context of the individual patient encounter.

Each PICO question should be answered by a clear, actionable recommendation, not a statement of fact. GRADE describes recommendations in terms of strength (strong or conditional/weak) and direction (for or against a management strategy). Strength refers to “the extent to which we can be confident that the composite desirable effects of a management strategy outweigh the composite undesirable effects” [13]. It is for this reason that GRADE provides a separate rating of evidence quality for each outcome. GRADE evidence profiles and summary of findings tables are organized accordingly.
However, the balance of benefit and harm is not necessarily the same for each clinical circumstance, and concepts such as “applicability” used in some guidelines are too vague and undefined to provide useful guidance [4]. Thus, GRADE has created Evidence to Decision Frameworks, which specify four essential domains to be explicitly considered [14, 15]:

- Certainty in evidence of effect of the management strategy
- Values and preferences of the patient/caregiver
- Balance of desirable and undesirable effects, from the patient's perspective
- Resource implications, acceptability, and equity

A strong recommendation implies that “all or almost all informed people would make the recommended choice for or against an intervention” [16]. A conditional (weak) recommendation implies that “most informed people would choose the recommended course of action, but a substantial number would not” [16]. Thus, a strong recommendation suggests uniformity; a conditional one suggests variability. Such conditional recommendations should be accompanied by an explicit statement of the factors that might influence the decision.

Great emphasis is placed on determining the patient’s perspective and circumstances as well as the relative importance of various outcomes to that individual. Together with the best available evidence and clinician expertise, explicit consideration of the individual patient's circumstance is what defines evidence-based practice [17]. How can this be achieved? Ideally, one would use empirical evidence from an SR that considers the importance that patients perceive about various health outcomes or utilities. GRADE has provided detailed guidance on how to evaluate such data [18, 19]. However, studies that included patients’ perceptions of outcome importance are seldom available for neurocritical care. Panels consisting of subject matter experts will base their estimate of patients’ values and preferences on their own clinical experience, with all the forms of bias that accompany such estimates. It is for these reasons that, as our survey has demonstrated, guideline panels increasingly incorporate public representation, commonly as patients and families/caregivers, to enrich their own perspective. This can be particularly helpful at the early stage of identifying and ranking outcomes in the generation of PICO questions, as well as in considering the impact of final recommendations.

A common and vexing problem arises when the evidence base for a PICO question proves to be of low or very low quality. Low (“the true effect may be substantially different from the estimate of the effect”) or very low certainty (“the true effect is likely to be substantially different from the estimate of the effect”) are encountered frequently in neurocritical care because many of the clinical studies available are NRS. GRADE assigns an initial “low” quality rating to all such studies, and deficiencies in design and conduct may lead to rating down the body of evidence further to “very low.” In this circumstance, guideline panels may be tempted to create recommendations that are not explicitly supported by an analysis of evidence quality. These may be termed “good practice” or “best practice” statements. These statements essentially represent the expert opinion (which GRADE does not consider to be evidence) of the panel. GRADE provides an analysis of when these may be justified [20] and suggests asking the following questions:

1. Is the statement clear and actionable?
2. Is the message really necessary?
3. Is the net benefit large and unequivocal?
4. Is the evidence difficult to collect and summarize?
5. Has the rationale been made explicit?
6. Should this statement be GRADE-ed? Does a large body of indirect evidence that can be convincingly linked to the PICO support the management strategy?

Thus, although there may be instances when these questions can be answered affirmatively, we recognize that overuse of such statements carries the risk of diminishing the confidence of guideline users in the rigor and trustworthiness of the guideline. The US Preventive Services Task Force specifically advises that “decision makers do not have the luxury of waiting for certain evidence. Even though evidence is insufficient, the clinician must still provide advice, patients must make choices, and policy makers must establish policies” [21]. This is consistent with GRADE guidance, which specifies the following:

Clinicians will rarely explore the evidence as thoroughly as a guideline panel, nor devote as much thought to the trade-offs, or the possible underlying values and preferences in the population. We therefore encourage panels to deal with their discomfort and to make recommendations even when confidence in effect estimate is low and/or desirable and undesirable consequences are closely balanced. Such recommendations will inevitably be weak, and may be accompanied by qualifications [16].

Summary of Lessons Learned
Review of a decade of work by NCS guideline panels together with a survey of the guideline practices of other organizations has revealed a number of opportunities for improvement in the conduct and methodological rigor of our clinical practice guidelines.
Common Themes from Successful Guideline Programs

The crucial role of the methodologist was evident in the GC survey. Thus far, NCS has used members who have undergone GRADE workshop training as methodologists. Other surveyed organizations employ staff who serve as methodologists across projects. Such individuals have deep experience and strong institutional support from other internal experts. These organizations also have a long history of creating guidelines that closely follow a well-established methodology, whether GRADE or other. Institutional memory is key.

The most successful guideline programs in our survey use professional methodologists to perform the SR and to produce the evidence synthesis, with evidence tables and meta-analysis meeting GRADE or Cochrane standards. Close collaboration between the methodologist, the panel chairs, and the oversight body (GC or other) throughout the project was a common theme. This coordination ensures that the topic and scope are both appropriate and feasible and that PICO questions are correctly formulated. The methodologist provides the writing panel with education and mentoring regarding the GRADE process so that additional advanced training in GRADE for chairs and panelists may not be needed. In addition, the methodologist benefits from frequent clinical guidance as the SR progresses.

Key Challenges with Previous NCS Practices

NCS has not developed a sufficient pool of experienced members with the ability to work intensively on successive projects. The GC has found that attendance at one or more workshops does not make one a methodologist. Competence in these techniques cannot be gained from slide presentations or by reading summary reviews. Past guideline chairs have typically not had formal training in GRADE or SR methodology. They have relied on an NCS member volunteer who has served as a GRADE methodology advisor after one or more guideline experiences and attendance at a GRADE workshop.

Panel members have usually been overwhelmed by the large commitment of time and effort involved in a formal SR. Inexperience with GRADE methodology may add to the burden on chairs as well as panelists. This may result in evidence summaries that deviate significantly from GRADE principles and practice, incorrectly formulated PICO questions, chosen topics with a scope that is excessive in relation to what is feasible, and recommendations in which the linkage to evidence quality is inappropriate and the rationale is unclear. Importantly, inexperience has contributed to significant difficulty in conforming to a clear timeline.

Key Improvements Going Forward

Scope and Topic Selection

Suggestions for guideline topics will be solicited from the GC and NCS membership. However, the process of choosing a topic will rely on established criteria and compatibility with GRADE methodology. Adherence to the following criteria can avoid common pitfalls and contribute to the success of future guideline efforts:

- The topic is commonly encountered in neurocritical care
- There is equipoise between different management strategies, resulting in significant variation in practice
- A reasonable amount of evidence is currently available from clinical trials and can be synthesized by using GRADE methodology
- The topic lends itself to 6–15 tightly constructed clinical questions with both defined populations or subgroups and critical and important outcomes that lend themselves to quantitative analysis
- There is sufficient overlap between adult and pediatric care that questions can address both populations, when appropriate and possible
- There has not been a recent high-quality guideline directly addressing the topic
- The topic has not been the subject of current or recent NCS projects

Panel Composition

The GC will make deliberate efforts to assemble a diverse panel of stakeholders across health care organizations, genders, roles, and specialties. The GC is also committed to including public members for the perspectives of patients and caregivers.

PICO Formulation

Panel chairs will draft PICO questions with input from the writing panel. These draft questions will be reviewed by the GC and by the methodology team prior to forwarding to an information specialist working with our methodological partners.

SR Conduct

The guideline practices survey revealed high standards for methodological rigor, consistency, and clarity among successful programs. To meet these standards, NCS will collaborate with a group of professional methodologists well versed in GRADE techniques. The society has committed to collaboration with Guidelines in Intensive Care, Development and Evaluation (GUIDE), a group of methodologists at McMaster University (Hamilton, Ontario, Canada). GUIDE will perform the entire SR and provide instruction in GRADE techniques to the team. Panelists
will gain from the streamlined and shortened process and reduction in workload.

**Consistent and Explicit Use of Evidence to Decision Framework**
A defining feature and innovation of GRADE is a structured process for applying population-level evidence to the individual patient encounter, referred to as the Evidence to Decision Framework. This process is facilitated and made clear, deliberate, and explicit by the use of GRADE software, which is provided and managed by our external methodology partners.

**Uniform Recommendation Format to Minimize Good Practice Statements**
Successful guideline programs strive for a consistent and recognizable format and brand in their products, even if methodologies differ. This is particularly true for the presentation of recommendations. NCS will follow strict GRADE guidance in formulating recommendations and minimize the inclusion of good practice statements based on expert opinion.

**Conclusions**
The GC performed a review of past NCS guideline practice and a survey of the practices of a number of other organizations. A principal finding was that most successful guideline programs incorporate professional methodologists into their working groups. By adopting this practice, NCS will be able to significantly improve the quality of its guidelines and establish a reliable, consistent, and trustworthy brand. To that end, the NCS Board has adopted the GC recommendation to collaborate with a team of external GRADE methodologists, an alliance that affirms the society’s commitment to developing high-quality resources to support and advance the practice of neurocritical care.

Embarking on this partnership, the GC anticipates three significant benefits. First, NCS members will find the experience to be more aligned with their expectations and hence will be more likely to volunteer their time on guideline development. Second, we expect guideline production to follow a more predictable and efficient timeline, with likely reduced time to publication. Last but not least, our guidelines will achieve a consistent level of quality that can be favorably compared to those of other societies. This could greatly improve the dissemination and implementation of our guidelines.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1007/s12028-021-01375-1.

**Author details**
1 Center for Nursing Science, University of California Davis Health, 2315 Stockton Blvd, North Addition 3015, Sacramento, CA 95817, USA. 2 Department of Neurosurgery and Neurology, University of Michigan, Ann Arbor, MI, USA. 3 Cumberland Pharmaceuticals, Nashville, TN, USA. 4 Division of Pediatric Neurology, University of Washington, Seattle, WA, USA. 5 Neuroscience Intensive Care Unit, Massachusetts General Hospital, Boston, MA, USA. 6 Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA. 7 Department of Clinical Pharmacy and Translational Science, College of Pharmacy, The University of Tennessee Health Science Center, Knoxville, TN, USA. 8 Departments of Neurology and Neurocritical Care, University of Florida Health, Jacksonville, FL, USA. 9 Division of Critical Care, Intensive Care Consortium/orange Park Medical Center, Orange Park, FL, USA. 10 Departments of Neurosurgery and Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, USA. 11 Division of Neurosurgery, Denver Health Medical Center, Denver, CO, USA.

**Author’s Contributions**
Lori K. Madden and Herb Fried: Lead contributors to the conception and design of the work; the acquisition, analysis, and interpretation of data; drafting and revision of the manuscript. Venkatakrishna Rajajee, Theresa Human, Mark S. Wainwright, Mary Guanci, Shraddha Mainali, Shaun Rowe, Diane McLaughlin, John Lunde, and Abhijit Lele: Acquisition and analysis of data, critical revision of manuscript. The final manuscript was approved by all authors.

**Conflict of interest**
None of the authors report relevant conflicts of interest to this work.

**Open Access**
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material, this article is licensed under a Creative Commons Attribution 4.0 International License, and is provided as is within the article.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Received:** 13 August 2021 **Accepted:** 7 October 2021 **Published online:** 2 November 2021

**References**
1. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3–23.
2. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical practice guidelines we can trust. Washington (DC): National Academies Press; 2011.
3. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol. 2011;64:407–15.
4. Dixon C, Dixon PE, Sultan S, et al. Guideline developers in the United States were inconsistent in applying criteria for appropriate Grading of recommendations, assessment, development and evaluation use. J Clin Epidemiol. 2020;124:193–9.
5. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines. 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64:395–400.
6. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
7. Wells GA, Shea B, O’Connell D, Peterson J, Welch V. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

8. Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.

9. Schunemann HJ, Cuello C, Akl EA, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105–14.

10. Wolff RF, Moons KGM, Riley RD, et al. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019;170:51–8.

11. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158:280–6.

12. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94.

13. Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66:726–35.

14. Alonso-Coello P, Oxman AD, Moberg J, et al. GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines. BMJ. 2016;353:i2089.

15. Alonso-Coello P, Schunemann HJ, Moberg J, et al. GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction. BMJ. 2016;353:i2016.

16. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66:719–25.

17. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence-based medicine: what it is and what it isn’t. BMJ. 1996;312:71–2.

18. Zhang Y, Coello PA, Guyatt GH, et al. GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences—inequality, imprecision, and other domains. J Clin Epidemiol. 2019;111:83–93.

19. Zhang Y, Alonso-Coello P, Guyatt GH, et al. GRADE Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences—risk of bias and indirectness. J Clin Epidemiol. 2019;111:94–104.

20. Guyatt GH, Alonso-Coello P, Schunemann HJ, et al. Guideline panels should seldom make good practice statements: guidance from the GRADE working group. J Clin Epidemiol. 2016;80:3–7.

21. Petitti DB, Teutsch SM, Barton MB, et al. Update on the methods of the U.S. preventive services task force: insufficient evidence. Ann Intern Med. 2009;150:199–205.